Table 3.
Multivariable analysis of transplants outcomes according to donor type
| MSD | MUD | Haplo | |||||
|---|---|---|---|---|---|---|---|
| Outcome | Reference | HR | 95% CI | p | HR | 95% CI | p |
| Acute GvHD | |||||||
| Grades II–IV | 1 | 1.42 | 0.92–2.19 | 0.11 | 1.6 | 1.08–2.37 | 0.02 |
| Grades III–IV | 1 | 1.22 | 0.56–2.64 | 0.61 | 1.76 | 0.92-3.37 | 0.09 |
| Chronic GvHD | |||||||
| Overall | 1 | 0.97 | 0.64–1.46 | 0.88 | 1.22 | 0.84–1.76 | 0.92 |
| Extensive type | 1 | 0.98 | 0.57–1.7 | 0.95 | 0.87 | 0.53–1.42 | 0.57 |
| NRM | 1 | 1.38 | 0.73–2.6 | 0.3 | 2.6 | 1.5–4.49 | < 0.001 |
| RI | 1 | 0.8 | 0.54–1.17 | 0.24 | 0.67 | 0.48–0.93 | 0.02 |
| LFS | 1 | 0.93 | 0.68–1.29 | 0.67 | 1.07 | 0.82-1.4 | 0.6 |
| OS | 1 | 0.91 | 0.64–1.31 | 0.62 | 1.17 | 0.86–1.59 | 0.32 |
| GRFS | 1 | 1.01 | 0.76–1.34 | 0.94 | 1.03 | 0.82–1.31 | 0.8 |
GvHD graft-versus-host disease, CI confidence interval, NRM non-relapse mortality, RI relapse incidence, LFS leukemia-free survival, OS overall survival, GRFS graft-versus-host disease and relapse-free survival